Dolutegravir-Based ART: Exploring Patient Safety and Acceptability Following National Roll-Out in Uganda
Loading...
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Research Square
Abstract
The World Health Organization recommends dolutegravir (DTG) as the backbone for rst-line and secondline antiretroviral therapy (ART) worldwide. However, little is known about the acceptability and tolerability of DTG-based ART at routine points-of-care in Uganda. We set out to explore the perceptions of ART clinic managers regarding the acceptability and tolerability of DTG-based ART since national roll-out in March 2018 in Uganda.
We adopted a qualitative descriptive design involving 49 ART clinic managers and clinicians. Between September 2020 and February 2021, we conducted 22 in-depth interviews with ART clinic managers and clinicians in 12 purposively selected health facilities across Uganda. The selection of study sites ensured diversity in facility ownership-type (public/private), level of service delivery (tertiary/secondary/primary) and the four major geographic sub-regions of Uganda. We conducted three focus group discussions with 27 ART clinicians in the participating facilities. Data were analyzed by thematic approach.
Description
Keywords
ART, Patient, DTG, Public
Citation
Zakumumpa, H., Kitutu, F. E., Ndagije, H. B., Diana, N. K., Ssanyu, J. N., & Kiguba, R. (2021). Dolutegravir-Based ART: Exploring Patient Safety and Acceptability Following National Roll-Out in Uganda. https://doi.org/10.21203/rs.3.rs-670284/v1